MedPath

Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com
Clinical Trials
Related News

Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate

Not Applicable
Completed
Conditions
Diabetes Mellitus Type 1
Interventions
Device: Accu-Chek Spirit Insulin Pump
First Posted Date
2007-12-07
Last Posted Date
2016-03-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
12
Registration Number
NCT00569452

A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: Epoetin alfa
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
First Posted Date
2007-11-19
Last Posted Date
2016-04-12
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
233
Registration Number
NCT00560404

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: RG1507
First Posted Date
2007-11-19
Last Posted Date
2016-11-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
34
Registration Number
NCT00560144

A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Phase 3
Withdrawn
Conditions
Anemia
Interventions
Drug: methoxy polyethylene glycol-epoetin beta
First Posted Date
2007-11-19
Last Posted Date
2016-08-24
Lead Sponsor
Hoffmann-La Roche
Registration Number
NCT00560547

A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.

Phase 4
Completed
Conditions
Anemia
Interventions
Drug: Pegasys
Drug: Ribavirin
Drug: epoetin beta [NeoRecormon]
First Posted Date
2007-11-19
Last Posted Date
2016-02-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
190
Registration Number
NCT00560274

A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: bevacizumab [Avastin]
Drug: Docetaxel
Drug: Standard chemotherapy
First Posted Date
2007-11-16
Last Posted Date
2014-11-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
72
Registration Number
NCT00559754

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis

Phase 3
Completed
Conditions
Anemia
Interventions
Drug: Methoxy polyethylene glycol-epoetin beta
First Posted Date
2007-11-16
Last Posted Date
2016-04-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
184
Registration Number
NCT00559637

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Phase 3
Completed
Conditions
Renal Anemia, Chronic
Interventions
Drug: Darbepoetin alfa
Drug: Methoxy polyethylene glycol-epoetin beta
First Posted Date
2007-11-16
Last Posted Date
2016-11-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
307
Registration Number
NCT00559273

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: 5-fluorouracil
Drug: Epidoxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Biological: Bevacizumab
First Posted Date
2007-11-16
Last Posted Date
2018-04-09
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
56
Registration Number
NCT00559845

A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: RO5045337
First Posted Date
2007-11-16
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
106
Registration Number
NCT00559533
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy